Article info
Correspondence response
Response to: ‘Effectiveness and safety of tocilizumab for the treatment of refractory systemic sclerosis associated interstitial lung disease: a case series’ by Narváez
- Correspondence to Dr Dinesh Khanna, Division of Rheumatology, University of Michigan, Ann Arbor, MI 48109, USA; khannad{at}med.umich.edu
Citation
Response to: ‘Effectiveness and safety of tocilizumab for the treatment of refractory systemic sclerosis associated interstitial lung disease: a case series’ by Narváez
Publication history
- Received September 28, 2018
- Revised October 9, 2018
- Accepted October 10, 2018
- First published October 23, 2018.
Online issue publication
October 15, 2019
Article Versions
- Previous version (23 October 2018).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.